Michael Sayers
Rheumatology · Colorado Springs, CONPI 1598764714
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.0% of the total across 115 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by AbbVie at 33.0% of the total. Reporting peaked in 2022 at $740 and has fallen 63.5% since, to $270 in 2023. That places this record below the midpoint for rheumatology clinicians in CO, where the typical reported total is $1,681.
Across 115 payments — averaging $16.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$629
- Amgen$503
- GSK$327
- Novartis$178
- Genentech USA, Inc.$76
- Pfizer$71
- plus $124 from 5 others
Across 39 payments — averaging $1780.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$29K
- Eli Lilly$21K
- AbbVie$18K
- Sanofi US Services Inc.$2K
What the payments were for
- Consulting fees$402%
- Food & beverage$1,85297%
- Education$171%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 39 | $629 |
| Amgen(2 entities) | 29 | $503 |
| GSK | 18 | $327 |
| Novartis | 13 | $178 |
| Genentech USA, Inc. | 4 | $76 |
| Pfizer | 6 | $71 |
| ANI Pharmaceuticals, Inc. | 2 | $43 |
| Boehringer Ingelheim | 1 | $29 |
| Mallinckrodt Hospital Products Inc. | 1 | $22 |
| Avion Pharmaceuticals | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
How this compares
$1,909 in reported general payments places this provider in the 50th percentile of 108 rheumatology providers in Colorado.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 24 | $206,480 |
| RinvoqUpadacitinib | 24 | $155,134 |
| Enbrel SureclickEtanercept | 16 | $130,493 |
| Hydroxychloroquine Sulfate | 44 | $2,165 |
| MethotrexateMethotrexate Sodium | 49 | $1,397 |
| Sulfasalazine DrSulfasalazine | 15 | $335 |
| Meloxicam | 11 | $79 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $629 | $155,13424 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 108 rheumatology providers in Colorado.
Other rheumatology in Colorado Springs
- David TheisColorado Springs$61K
- Christopher ChongColorado Springs$11K
- Artur KalutaColorado Springs$7K
- Megan MacneilColorado Springs$6K
- Christopher InserraColorado Springs$5K
- Dan CristescuColorado Springs$4K
- James LevineGreeley$130K
- Aryeh FischerDenver$114K
- Adam BerlinbergDenver$94K
- Rennie McCabeDenver$58K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.